Predictive marker for response to trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer patients.

ABSTRACT:

Objective

Trifluridine/tipiracil (FTD/TPI) is one of the options for late-line treatment of colorectal cancer (CRC). However, the specific patient populations that would particularly benefit from it remain unclear. This study attempted to identify predictive markers of chemotherapy efficacy with trifluridine/tipiracil (FTD/TPI), focusing on the RNA-editing enzyme adenosine deaminase acting on RNA 1 (ADAR1) expression and neutrophil-lymphocyte ratio (NLR).

Methods

To assess the effectiveness of FTD/TPI in CRC patients, we retrospectively analyzed 72 CRC patients at Okayama University Hospital from 2014 to 2022.

Results

Adding bevacizumab to FTD/TPI resulted in a more prolonged progression-free survival (PFS), consistent with the SUNLIGHT study findings (p = 0.0028). Am

SUBMITTER: Takahashi T 

PROVIDER: S-EPMC11694457 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature